(NASDAQ:MRKR), Marker Therapeutics initiated Phase 1 RAPID study to investigate Multi-Antigen Recognizing (MAR) T cells as an Off-the-Shelf (OTS) product to accelerate time to treatment OTS product was well tolerated – safety data consistent with other MAR-T cell studies HOUSTON, Oct. 06, 2025 (GLOBE NEWSWIRE) — Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company […]
(NASDAQ:CNTX), PHILADELPHIA, Oct. 06, 2025 (GLOBE NEWSWIRE) — Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced two posters will be presented at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting, being held November 7-9, 2025, at
(NasdaqGM:BWMN), RESTON, Va., Oct. 06, 2025 (GLOBE NEWSWIRE) — Bowman Consulting Group Ltd. (NASDAQ: BWMN), a national engineering services and project management firm, today announced it has acquired the assets of California-based Sierra Overhead Analytics (“SOA”) and its technology affiliate ORCaS, Inc., two companies under common control. The acquisition expands Bowman's energy practice and extends
— Leadership and focus: Radical Semiconductor co-founders Sean Hackett and Zach Belateche have joined BTQ full-time, with Anne Reinders continuing as Head of Cryptography. Hackett will lead silicon product, and Belateche will lead hardware security, accelerating commercialization across CASH and QCIM. — CASH performance and relevance: CASH is a memory centric acceleration architecture for post-quantum
— AUM & Continued Monthly Net Inflows: As of September 30, 2025, Valour reported assets under management (AUM) of $987 million, marking a 1.3% increase month-over-month. September net inflows totaled $23.6 million, bringing year-to-date inflows to $115.3 million. These figures highlight growing investor demand for Valour's ETP offerings. — Highest Average Quarterly AUM: For the
Western Copper and Gold Corporation (“Western” or the “Company”) (TSX: WRN) (NYSE American: WRN) is pleased to announce the submission of its Environmental and Socio-economic Effects Statement (“ESE Statement”) for the proposed Casino Project (“Casino” or the “Project”) to the Yukon Environmental and Socio-economic Assessment Board (“YESAB”). https://mma.prnewswire.com/media/2789223/Western_Copper_and_Gold_Corporation_WESTERN_COPPER_AND_GOLD_ANNO.jpg The submission is an important step in
AllianceBernstein Holding L.P. (NYSE: AB) and AllianceBernstein L.P. (“AB”), a leading global investment management firm, announced today the launch of AB California Intermediate Municipal ETF (“CAM”) as an actively managed exchange-traded fund (ETF) on the New York Stock Exchange. Global trading firm Jane Street is the Lead Market Maker for the Fund. “Today, we announce
Grant funds two-thirds of a NIS 1.23 million ($373K) project to strengthenScinai Bioservices' small-batch fill and finish capabilities, addressing a critical need among early-stage biotech companies in Israel and abroad Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) (“Scinai” or the “Company”), a biopharmaceutical company with a growing boutique contract development and manufacturing organization (CDMO) business unit, Scinai
Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program GlobeNewswire October 06, 2025 Marker Therapeutics initiated Phase 1 RAPID study to investigate Multi-Antigen Recognizing (MAR) T cells as an Off-the-Shelf (OTS) product to accelerate time to treatment OTS product was well tolerated – safety data consistent with other MAR-T cell studies HOUSTON, Oct. 06, 2025
Context Therapeutics Announces Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting GlobeNewswire October 06, 2025 PHILADELPHIA, Oct. 06, 2025 (GLOBE NEWSWIRE) — Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced two posters will